Literature DB >> 11740738

Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure.

M E Roland1, J N Martin, R M Grant, N S Hellmann, J D Bamberger, M H Katz, M Chesney, K Franses, T J Coates, J O Kahn.   

Abstract

In a nonrandomized study of nonoccupational postexposure prophylaxis (PEP), a cross-sectional evaluation of subjects who were the source of human immunodeficiency (HIV) exposure was performed to characterize partners of index subjects seeking nonoccupational PEP against HIV. Among 401 index subjects, 64 (16%) recruited a source subject. Those in a steady relationship and those who knew that the source subject was HIV antibody positive were more likely to recruit their source subject. Source subjects reported high rates of past (78%) and current (69%) antiretroviral use; 46% of those using antiretroviral drugs had detectable plasma HIV-1 RNA levels. Antiretroviral resistance was detected in many source subjects who reported any use of antiretrovirals and was rare among source subjects who reported no history of antiretroviral use. Clinicians often make treatment decisions on the basis of incomplete knowledge of the source subject's HIV status or antiretroviral treatment history. The treatment history, particularly nonuse of a class of antiretroviral drugs, can be used to predict drug resistance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11740738     DOI: 10.1086/324580

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  2 in total

1.  Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure.

Authors:  Rose Tsui; Belinda L Herring; Jason D Barbour; Robert M Grant; Peter Bacchetti; Alex Kral; Brian R Edlin; Eric L Delwart
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

Review 2.  Management of occupational and nonoccupational postexposure HIV prophylaxis.

Authors:  Mitchell H Katz; Julie Louise Gerberding
Journal:  Curr HIV/AIDS Rep       Date:  2004-12       Impact factor: 5.495

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.